Clinical Trial Update: OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of OriCAR-017, a CAR-T cell therapy, for relapsed/refractory multiple myeloma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• OriCAR-017

Snippet

Sponsor: OriCell Therapeutics Co., Ltd. | Conditions: Relapsed and/or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING